DIATER Group
DIATER laboratories
Leaders in molecular immunotherapy
DIATER Laboratories is dedicated to the manufacture of biopharmaceutical products. At its headquarters in Leganés (Madrid. Spain), DIATER Laboratories has more than 4000 m2 of facilities that house 3 different production units, focused on the diagnosis and treatment of allergies, as well as the production of vaccines and microbiological autovaccines. The state-of-the-art R&D and applications laboratories, equipped with cutting-edge technologies, are respectively responsible for the study and development of new products. DIATER Laboratories has also 2 subsidiaries, in Portugal and in Germany.
Allergen Servilab
Raw material specialists
Allergen Servilab is a company specialised in the production of raw materials for the production of allergenic extracts. The location of the company's facilities, in La Horcajada - Ávila, a privileged rural environment, which provides access to top quality pollen sources. Allergen Servilab has a unit specialised in the cultivation of mites for the production of allergenic extracts. In addition to pollens and mites, it produces allergenic fungi, hymenoptera venom and animal epithelia.
DIATER in the word
Our international expansion
DIATER is in the midst of an international expansion phase. DIATER currently markets its products in more than 40 countries. It has a Portuguese subsidiary, Laboratórios DIATER Lda., based in the Lisbon Metropolitan Area and a German subsidiary, DIATER Deutschland GmbH, based in Munich. In addition, DIATER has established an extensive network of specialised distributors who ensure that everyday thousands of people around the world benefit from the use of DIATER solutions.
History
Internationalization as a Growth Vector
DIATER, Laboratorio de Diagnóstico y Aplicaciones Terapéuticas, S.A., was established in 1999 in Madrid (Spain), with the mission of researching, developing, and marketing innovative diagnostic tools and treatments for allergy patients.
Since its founding, DIATER has been dedicated to advancing drug allergy diagnostics, notably by pioneering the first method to detect beta-lactam allergies, utilizing both the major and minor determinants of penicillin. This product is registered in Germany and complies with EAACI guidelines.
Following this innovative vision in the area of allergen-specific immunotherapy, DIATER was a pioneer in developing the first subcutaneous molecular treatment with the purified protein of the fungus Alternaria alternata, Alt a 1, available for allergic patients to fungi, a milestone in the immunotherapy market.
Continuing with this same line of research, the family of molecular immunotherapy treatments has been extended to include the first molecular treatment with native allergen for cypress sensitisation with Cup a 1 and for the treatment of the house dust mite allergic patients with the clinical relevant allergens Der p 1, Der p 2 and Der p 23.
In addition, providing solutions for polysensitized patients, we have developed different types of immunotherapy adapted to their needs: subcutaneous treatments with high-dose allergoids without aluminum (chemically modified allergens); sublingual treatments with a wide range of available native allergens; and the first intradermal immunotherapy treatment with the Phleum pratense allergen; as well as treatments against hymenoptera venom allergy with our own optimized production.
Due to the constant growth of the company and its consolidation in the Spanish market, DIATER is strengthening its internationalization process, with subsidiaries in Portugal and in Germany, and is present in more than 40 countries worldwide.
With an ongoing commitment to innovation, DIATER continues to provide valuable solutions to improve the quality of life of allergy patients.